Could CAR-T cells tame severe colitis? early trial launches
NCT ID NCT07435779
First seen Mar 04, 2026 · Last updated Jun 22, 2026 · Updated 11 times
Summary
This early-phase trial tests whether a patient's own immune cells, engineered to target BCMA and/or CD19, can calm severe ulcerative colitis that hasn't responded to other treatments. Twelve adults with moderate-to-severe active disease will receive a single infusion of these CAR-T cells. The main goal is to check safety and see if it leads to clinical remission within 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Foresea Life Insurance Guangzhou General Hospital
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CAR-T cells (BCMA, CD19, or both) made from the patient's own blood
What this could lead to
If it works, this could point toward a new treatment for severe ulcerative colitis that doesn't respond to standard therapies.
What could go wrong
This is a very early, small trial with only 12 people. CAR-T therapy can cause serious side effects like cytokine release syndrome and nerve problems. It may not work or may be too risky.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.